Transcode Therapeutics Stock EBITDA
| RNAZ Stock | USD 0.78 0.04 5.41% |
Transcode Therapeutics fundamentals help investors to digest information that contributes to Transcode Therapeutics' financial success or failures. It also enables traders to predict the movement of Transcode Stock. The fundamental analysis module provides a way to measure Transcode Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transcode Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -16.2 M | -15.4 M |
Transcode | EBITDA |
Transcode Therapeutics Company EBITDA Analysis
Transcode Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Transcode Therapeutics EBITDA | (17.97 M) |
Most of Transcode Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transcode Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Transcode EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Transcode Therapeutics is extremely important. It helps to project a fair market value of Transcode Stock properly, considering its historical fundamentals such as EBITDA. Since Transcode Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Transcode Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Transcode Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Transcode Ebitda
According to the company disclosure, Transcode Therapeutics reported earnings before interest,tax, depreciation and amortization of (17.97 Million). This is 102.05% lower than that of the Biotechnology sector and 117.95% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.46% higher than that of the company.
Transcode EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transcode Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transcode Therapeutics could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics of similar companies.Transcode Therapeutics is currently under evaluation in ebitda category among its peers.
Transcode Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Transcode Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Transcode Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Transcode Therapeutics' value.| Shares | First Personal Financial Services Inc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 8.7 K | Tower Research Capital Llc | 2024-12-31 | 926 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 304 | Bank Of America Corp | 2024-12-31 | 4.0 | Captrust Financial Advisors | 2024-12-31 | 0.0 | Susquehanna International Group, Llp | 2024-09-30 | 0.0 |
Transcode Fundamentals
| Return On Equity | -4.9 | ||||
| Return On Asset | -1.29 | ||||
| Current Valuation | (1.19 M) | ||||
| Shares Outstanding | 696.25 K | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 22.36 % | ||||
| Number Of Shares Shorted | 162.85 K | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | (17.97 M) | ||||
| Net Income | (18.55 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 450.57 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 3.16 X | ||||
| Cash Flow From Operations | (18.07 M) | ||||
| Short Ratio | 0.16 X | ||||
| Earnings Per Share | 5,572 X | ||||
| Target Price | 20.0 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 541.54 K | ||||
| Total Asset | 5.17 M | ||||
| Retained Earnings | (46.42 M) | ||||
| Working Capital | 964.85 K | ||||
| Net Asset | 5.17 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.